Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma

Ependymoma

Posterior fossa group A and ZFTA-fusion tumours, where surgery and radiotherapy remain the only standard.

Live from ClinicalTrials.gov + PubMed, fetched 2026-11-12 10:14 UTC. Every row links to its source record.

Principal investigators and study chairs named on the registry for ependymoma, ranked by a published score: 3 per Phase 2+ trial they lead, 1 per other trial role, 2 per oral or late-breaking talk and 0.5 per poster in our verified 2026 meeting rows, each halved every 24 months. Paper authorship is not scored yet. PubMed counts are author name plus indication, for the top 12; names are as the registry spells them, so a common name can pool several people. Open a row for their trials and links to their papers.

Adam J Esbenshade

Children's Oncology Group

score 3

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT07848568 · Children's Oncology Group · Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma

Eric M Thompson

Washington University School of Medicine

score 3

5 papers

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT06639607 · Washington University School of Medicine · PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

Marielle E Yohe

National Cancer Institute (NCI)

score 3

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT07891286 · National Cancer Institute (NCI) · Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults

Jaime Gállego Pérez de Larraya

Cancer Center Clínica Universidad de Navarra

score 2.5

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT07424092 · Clinica Universidad de Navarra, Universidad de Navarra · Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors

Sabine Mueller

University of California, San Francisco

score 2.5

6 papers

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT07226453 · University of California, San Francisco · Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma

Santhosh A Upadhyaya

University of Michigan, C. S. Mott Children's Hospital

score 2.5

3 papers

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT07226453 · University of California, San Francisco · Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma

Kevin A Camphausen

National Cancer Institute (NCI)

score 1.1

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 1.1 = 1.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT06161519 · National Cancer Institute (NCI) · PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

Susan Chi

Dana-Farber Cancer Institute

score 0.9

9 papers

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.9 = 0 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07390539 · Robbie Majzner · B7-H3.CD28Z.CART in CNS Neoplasms

Margot Lazow

Nationwide Children's Hospital

score 0.8

1 papers

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.8 = 0.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT05278208 · Nationwide Children's Hospital · Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

Matthias Karajannis

Memorial Sloan Kettering Cancer Center

score 0.6

14 papers

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.6 = 0.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04743661 · Pediatric Brain Tumor Consortium · 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

John Ligon

University of Florida

score 0.6

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.6 = 0 leading Phase 2+ trials + 0.6 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07031765 · University of Florida · Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma

Marta Osuna Marco

HM Monteprincipe

score 0.5

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.5 = 0 leading Phase 2+ trials + 0.5 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT06607692 · Fundación de investigación HM · Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Brian Rood

Children's National Research Institute

score 0.5

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.5 = 0 leading Phase 2+ trials + 0.5 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT06193759 · Children's National Research Institute · Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

Andrea T Franson

Children's Oncology Group

score 0.4

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.4 = 0.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04320888 · National Cancer Institute (NCI) · Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Christine A Pratilas

Children's Oncology Group

score 0.4

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.4 = 0.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04284774 · National Cancer Institute (NCI) · Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Jeffrey M. Treiber

The University of Texas Health Science Center, Houston

score 0.4

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.4 = 0 leading Phase 2+ trials + 0.4 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT06466798 · Jeffrey Treiber · Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

Elizabeth D Alva

Children's Oncology Group

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04195555 · National Cancer Institute (NCI) · Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Scott Plotkin

Massachusetts General Hospital

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04374305 · Scott R. Plotkin, MD, PhD · Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

Theodore S Johnson

Augusta University

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04049669 · Theodore S. Johnson · Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

Christopher DeRenzo

St. Jude Children's Research Hospital

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT05835687 · St. Jude Children's Research Hospital · Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Diana Azzam

Florida International University

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT05857969 · Florida International University · Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Giedre Krenciute

St. Jude Children's Research Hospital

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT05835687 · St. Jude Children's Research Hospital · Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Kelsey Bertrand

St. Jude Children's Research Hospital

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT05835687 · St. Jude Children's Research Hospital · Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Maggie Fader

Nicklaus Children's Hospital

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT05857969 · Florida International University · Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Alice Lee

Children's Oncology Group

score 0.2

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.2 = 0.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03210714 · National Cancer Institute (NCI) · Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Kieuhoa T Vo

Children's Oncology Group

score 0.2

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.2 = 0.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03698994 · National Cancer Institute (NCI) · Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Meredith S Irwin

Children's Oncology Group

score 0.2

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.2 = 0.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03213652 · National Cancer Institute (NCI) · Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Rajen Mody

Children's Oncology Group

score 0.2

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.2 = 0.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03526250 · National Cancer Institute (NCI) · Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Clare Twist

Roswell Park Comprehensive Cancer Center

score 0.2

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.2 = 0 leading Phase 2+ trials + 0.2 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT04978727 · Children's Oncology Group · A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Meenakshi Hegde

Baylor College of Medicine

score 0.2

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.2 = 0 leading Phase 2+ trials + 0.2 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT04903080 · Children's Oncology Group · HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma

Kevin Camphausen

National Cancer Institute (NCI)

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

Donald W Parsons

Children's Oncology Group

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03155620 · National Cancer Institute (NCI) · Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Heather M. Conklin

St. Jude Children's Research Hospital

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03194906 · St. Jude Children's Research Hospital · Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors

Katherine A Janeway

Children's Oncology Group

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03213704 · National Cancer Institute (NCI) · Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Susan N Chi

Children's Oncology Group

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03213665 · National Cancer Institute (NCI) · Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Theodore W Laetsch

Children's Oncology Group

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03213678 · National Cancer Institute (NCI) · Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Thomas Cash

Emory University

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT02574728 · Emory University · Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors

Thomas Kaley

Memorial Sloan Kettering Cancer Center

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03220646 · Memorial Sloan Kettering Cancer Center · Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors

David R Grosshans

M.D. Anderson Cancer Center

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT03750513 · M.D. Anderson Cancer Center · LET Optimized IMPT in Treating Pediatric Patients With Ependymoma

Gregory Friedman

M.D. Anderson Cancer Center

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in ependymoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT03911388 · M.D. Anderson Cancer Center · HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors